Understanding Oral Wegovy: Insights from Dr. Spencer Nadolsky and Dr. Carl Nadulski

Welcome back to the Docs Who Lift podcast! In this episode, hosted by Dr. Spencer Nadolsky and co-hosted by endocrinologist Dr. Carl Nadulski, the discussion revolves around the recently launched oral medication Wegovy, a form of semaglutide. The hosts share their experiences, insights, and the implications of transitioning from injections to oral medication for weight management.

What is Oral Wegovy?

Oral Wegovy is a new oral formulation of semaglutide, which is about ten times more potent than its injectable counterpart. This special formulation utilizes a technology known as SNAC that helps protect the drug from stomach acid, allowing it to be effectively absorbed into the bloodstream.

Transitioning from Injections to Oral Wegovy

Dr. Nadolsky shares his approach to transitioning patients from the injectable form of semaglutide to the oral version. He notes that if a patient is using 2.4 mg of the injectable, they can potentially switch to a 25 mg oral dose, although he advises starting conservatively due to differences in tolerance levels between the two formulations.

Understanding Dosage Equivalence

During the discussion, the hosts highlight the importance of understanding dosage equivalence when switching medications. They emphasize that the starting dosage for oral Wegovy is 1.5 mg and that titration should be done carefully based on individual patient needs and tolerability.

Insights from the SURMOUNT-4 Trial

They also delve into the findings from the SURMOUNT-4 trial, which evaluated weight loss and maintenance following the use of semaglutide. The trial revealed that while many participants experienced weight regain after stopping the medication, a significant portion managed to maintain their weight loss. This highlights the variability in individual responses to weight management drugs.

Weight Maintenance and Regain

• 17% of participants maintained their weight loss after discontinuing the drug.
• 25% regained between 25% and 50% of the weight lost.
• 33% regained between 50% and 75% of the weight lost.
• 25% regained more than 75% of the weight lost.

This information is crucial for patients considering weight management strategies and reinforces the need for personalized approaches in treatment.

The Cost of Oral Wegovy

Dr. Nadolsky discusses the cost implications of Oral Wegovy, noting that while it is currently more affordable than its injectable counterpart, patients may still face significant out-of-pocket expenses. He emphasizes the need for transparency and advocacy for lower medication prices.

Conclusion

The transition to Oral Wegovy marks a significant advancement in weight management options, but it comes with its challenges, including differences in tolerability, dosing, and cost. As Dr. Nadolsky and Dr. Nadulski stress, individualized treatment plans and ongoing patient support are essential for successful weight management.

Key Takeaways

• Oral Wegovy is an effective alternative to injectable semaglutide, with a unique formulation for better absorption.
• Transitioning from injections to oral medication requires careful consideration of dosage equivalence and patient tolerability.
• The SURMOUNT-4 trial indicates variability in weight maintenance after discontinuation of the drug.
• Cost remains a significant barrier for many patients seeking effective weight management solutions.

TLDR

The podcast episode discusses the launch of Oral Wegovy, a new oral formulation of semaglutide, and highlights its potential benefits and challenges. The hosts emphasize the importance of personalized treatment plans and ongoing support for successful weight management.

Health-Related Compounds Mentioned

• Peptides: Semaglutide
• GLP-1 Drugs: Semaglutide

Authors

• Dr. Spencer Nadolsky
• Dr. Carl Nadulski